Catalent Pharma has acquired advanced fine powder filling capability from Harro Hofliger. With the purchase of Harro Hofliger’s Omnidose filling equipment, Catalent now offers its customers fully scaleable dry powder inhaler (DPI) filling capability.
Subscribe to our email newsletter
The company said that the technology is to be housed in Catalent’s Research Triangle Park, North Carolina facility, provides a flexible platform to reliably support all clinical manufacture through Phase II/III and a scaleable path to higher volume late stage clinical and commercial manufacturing.
Harro Hofliger claims that its equipment is an advanced technology specialised in powder filling for microdosing, in the 1 – 300mg of powder range, into an array of DPI formats to include both capsule-based and pre-metered blister device formats.
Reportedly, the new capability gives Catalent a full range of pulmonary and nasal services, filling a gap in the marketplace for advanced powder filling capabilities. Catalent will now be able to serve as a one-stop-shop for the development of all inhalation dosage forms, possessing both the capital assets and technical experience.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.